Meta- and cost-effectiveness analysis of commercial weight loss strategies

Obesity

Volumn 22, Issue 9, 2014, Pages 1942-1951

  Finkelstein, Eric A ^a,b   Kruger, Eliza ^a  

^a DUKE NUS MEDICAL SCHOOL   (Singapore)

^b DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LORCASERIN; PHENTERMINE PLUS TOPIRAMATE; PLACEBO; TETRAHYDROLIPSTATIN;

BODY MASS; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG EFFICACY; HEALTH PROGRAM; HUMAN; LIFESTYLE MODIFICATION; OBESITY; ONE MEAL REPLACEMENT PROGRAM; PROGRAM COST EFFECTIVENESS; QUALITY ADJUSTED LIFE YEAR; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SYSTEMATIC REVIEW; TREATMENT OUTCOME; VTRIM PROGRAM; WEIGHT REDUCTION; WEIGHT WATCHER PROGRAM; BODY WEIGHT; COST BENEFIT ANALYSIS; ECONOMICS; META ANALYSIS; PRACTICE GUIDELINE;

BODY WEIGHT; COST-BENEFIT ANALYSIS; HUMANS; OBESITY; PRACTICE GUIDELINES AS TOPIC; WEIGHT LOSS;

EID: 84906736958     PISSN: 19307381     EISSN: 1930739X     Source Type: Journal    
DOI: 10.1002/oby.20824     Document Type: Review

References (80)

1. Tsai AG, Wadden TA,. Systematic review: an evaluation of major commercial weight loss programs in the United States. Ann Intern Med 2005; 142: 56-66.
2. Yanovski SZ, Yanovski JA,. Long-term drug treatment for obesity: a systematic and clinical review. JAMA 2013; 311: 74-86.
3. Siegel JE, Weinstein MC, Russell LB, Gold MR,. Recommendations for reporting cost-effectiveness analyses. JAMA 1996; 276: 1339-1341.
4. Medi-Span. Price RX Database. Wolters Kluwer Health. 2013.
5. Medicare. Fee Schedule, Payment and Reimbursement Benefit Guideline, CPT Code Billing. Office visit CPT, E&M code fee schedule-Florida Medicare. 2013. Available at: http://www.medicarepaymentandreimbursement.com/2013/01/ office-visit-cpt-e-code-fee-schedule.html. Accessed on January 17, 2014.
6. Hall KD, Sacks G, Chandramohan D, et al. Quantification of the effect of energy imbalance on bodyweight. Lancet 2011; 378: 826-837.
7. Gallup. Americans Spend $151 a Week on Food; the High-Income, $180. August 2, 2012. Available at: http://www.gallup.com/poll/156416/ americans-spend-151-week-food-high-income-180.aspx. Accessed on March 3, 2014.
8. Bureau of Labor Studies. CPI Inflation Calculator. 2013. Available at: http://www.bls.gov/data/inflation-calculator.htm. Accessed on March 5, 2014.
9. Gold BC, Burke S, Pintauro S, Buzzell P, Harvey-Berino J,. Weight loss on the web: a pilot study comparing a structured behavioral intervention to a commercial program. Obesity (Silver Spring, Md) 2007; 15: 155-164.
10. Dansinger M, Gleason J, Griffith JL, Selker HP, Schaefer EJ,. Comparison of the atkins, ornish, weight watchers, and zone diets for weight loss and heart disease risk reduction: a randomized trial. JAMA 2005; 293: 43-53.
11. Collaboration RTC. Review Manager (RevMan). 5.2. The Nordic Cochrane Centre, Copenhagen: The Cochrane Collaboration; 2008.
12. DerSimonian R, Laird N,. Meta-analysis in clinical trials. Control Clin Trials 1986; 7: 177-188.
13. Gadde KM, Allison DB, Ryan DH, et al. Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial. Lancet 2011; 377: 1341-1352.
14. Ware JE Jr, Kosinski M, Keller SD,. A 12-item short-form health survey: construction of scales and preliminary tests of reliability and validity. Med Care 1996; 34: 220-233.
15. Brazier JE, Roberts J,. The estimation of a preference-based measure of health from the SF-12. Med Care 2004; 42: 851-859.
16. Reynolds MR, Zimetbaum P, Josephson ME, Ellis E, Danilov T, Cohen DJ,. Cost-effectiveness of radiofrequency catheter ablation compared with antiarrhythmic drug therapy for paroxysmal atrial fibrillation. Circ Arrhythm Electrophysiol 2009; 2: 362-369.
17. Katon W, Russo J, Sherbourne C, et al. Incremental cost-effectiveness of a collaborative care intervention for panic disorder. Psychol Med 2006; 36: 353-363.
18. Bensink M, Wootton R, Irving H, et al. Investigating the cost-effectiveness of videotelephone based support for newly diagnosed paediatric oncology patients and their families: design of a randomised controlled trial. BMC Health Serv Res 2007; 7: 38.
19. Heshka S, Anderson JW, Atkinson RL, et al. Weight loss with self-help compared with a structured commercial program. JAMA 2003; 289: 1792-1798.
20. Jebb SA, Ahern AL, Olson AD, et al. Primary care referral to a commercial provider for weight loss treatment versus standard care: a randomised controlled trial. Lancet 2011; 378: 1485-1492.
21. Rock CL, Flatt SW, Sherwood NE, Karanja N, Pakiz B, Thomson CA,. Effect of a free prepared meal and incentivized weight loss program on weight loss and weight loss maintenance in obese and overweight women: a randomized controlled trial. JAMA 2010; 304: 1803-1810.
22. Rock CL, Pakiz B, Flatt SW, Quintana EL,. Randomized trial of a multifaceted commercial weight loss program. Obesity 2007; 15: 939-949.
23. O'Neil PM, Smith SR, Weissman NJ, et al. Randomized placebo-controlled clinical trial of lorcaserin for weight loss in type 2 diabetes mellitus: the BLOOM-DM study. Obesity 2012; 20: 1426-1436.
24. Bakris G, Calhoun D, Egan B, Hellmann C, Dolker M, Kingma I,. Orlistat improves blood pressure control in obese subjects with treated but inadequately controlled hypertension. J Hypertens 2002; 20: 2257-2267.
25. Broom I, Wilding J, Stott P, Myers N,. Randomised trial of the effect of orlistat on body weight and cardiovascular disease risk profile in obese patients: UK multimorbidity study. Int J Clin Pract 2002; 56: 494.
26. Davidson MH, Hauptman J, DiGirolamo M, et al. Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat. JAMA 1999; 281: 235-242.
27. Derosa G, Cicero AF, D'Angelo A, Fogari E, Maffioli P,. Effects of 1-year orlistat treatment compared to placebo on insulin resistance parameters in patients with type 2 diabetes. J Clin Pharm Ther 2012; 37: 187-195.
28. Derosa G, Mugellini A, Ciccarelli L, Fogari R,. Randomized, double-blind, placebo-controlled comparison of the action of orlistat, fluvastatin, or both an anthropometric measurements, blood pressure, and lipid profile in obese patients with hypercholesterolemia prescribed a standardized diet. Clin Ther 2003; 25: 1107-1122.
29. Finer N, James W, Kopelman P, Lean M, Williams G,. One-year treatment of obesity: a randomized, double-blind, placebo-controlled, multicentre study of orlistat, a gastrointestinal lipase inhibitor. Int J Obes Relat Metab Disord 2000; 24: 306-313.
30. Hanefeld M, Sachse G,. The effects of orlistat on body weight and glycaemic control in overweight patients with type 2 diabetes: a randomized, placebo-controlled trial. Diabetes Obes Metab 2002; 4: 415-423.
31. Hauptman J, Lucas C, Boldrin MN, Collins H, Segal KR,. Orlistat in the long-term treatment of obesity in primary care settings. Arch Fam Med 2000; 9: 160.
32. Hollander PA, Elbein SC, Hirsch IB, et al. Role of orlistat in the treatment of obese patients with type 2 diabetes: a 1-year randomized double-blind study. Diabetes Care 1998; 21: 1288-1294.
33. Kelley DE, Bray GA, Pi-Sunyer FX, et al. Clinical efficacy of orlistat therapy in overweight and obese patients with insulin-treated type 2 diabetes: a 1-year randomized controlled trial. Diabetes Care 2002; 25: 1033-1041.
34. Krempf M, Louvet JP, Allanic H, Miloradovich T, Joubert JM, Attali JR,. Weight reduction and long-term maintenance after 18 months treatment with orlistat for obesity. Int J Obes Relat Metab Disord 2003; 27: 591-597.
35. Miles JM, Leiter L, Hollander P, et al. Effect of orlistat in overweight and obese patients with type 2 diabetes treated with metformin. Diabetes Care 2002; 25: 1123-1128.
36. Rössner S, Sjöström L, Noack R, Meinders A, Noseda G,. Weight loss, weight maintenance, and improved cardiovascular risk factors after 2 years treatment with orlistat for obesity. Obes Res 2012; 8: 49-61.
37. Sjostrom L, Rissanen A, Andersen T, et al. Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. European Multicentre Orlistat Study Group. Lancet 1998; 352: 167-172.
38. Swinburn BA, Carey D, Hills AP, et al. Effect of orlistat on cardiovascular disease risk in obese adults. Diabetes Obes Metab 2005; 7: 254-262.
39. Torgerson JS, Hauptman J, Boldrin MN, Sjöström L,. XENical in the Prevention of Diabetes in Obese Subjects (XENDOS) Study A randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care 2004; 27: 155-161.
40. Lindgärde F,. The effect of orlistat on body weight and coronary heart disease risk profile in obese patients: the Swedish Multimorbidity Study. J Intern Med 2000; 248; 245-254.
41. Weight Watchers. Weightwatchers.com: Monthly Pass Learn More. 2013. Available at: http://www.weightwatchers.com/templates/marketing/Landing-1col- nonav.aspx?PageId=1080551. Accessed on October 24, 2013.
42. Blake P,. Vtrim review. 2013. Available at: http://www.dietspotlight.com/ vtrim-review/. Accessed on October 26, 2013.
43. J. Craig,. Jenny Craig Cuisine Menu. 2013. Available at: http://www.jennycraig.com/site/cuisine/cuisine.jsp ?. Accessed on November 1, 2013.
44. Braithwaite RS, Meltzer DO, King JT Jr, Leslie D, Roberts MS,. What does the value of modern medicine say about the $50,000 per quality-adjusted life-year decision rule? Med Care 2008; 46: 349-356.
45. Grosse SD,. Assessing cost-effectiveness in healthcare: history of the $50,000 per QALY threshold. Expert Rev Pharmacoecon Outcomes Res 2008; 8: 165-178.
46. Womble LG, Wadden TA, McGuckin BG, Sargent SL, Rothman RA, Krauthamer-Ewing ES,. A randomized controlled trial of a commercial internet weight loss program. Obes Res 2004; 12: 1011-1018.
47. Cheskin LJ, Mitchell AM, Jhaveri AD, et al. Efficacy of meal replacements versus a standard food-based diet for weight loss in type 2 diabetes: a controlled clinical trial. Diabetes Educ 2008; 34: 118-127.
48. Rothacker DQ, Staniszewski BA, Ellis PK,. Liquid meal replacement vs traditional food: a potential model for women who cannot maintain eating habit change. J Am Diet Assoc 2001; 101: 345-347.
49. Li Z, Treyzon L, Chen S, Yan E, Thames G, Carpenter CL,. Protein-enriched meal replacements do not adversely affect liver, kidney or bone density: an outpatient randomized controlled trial. Nutr J 2010; 9: 72.
50. Ashley JM, St Jeor ST, Schrage JP, et al. Weight control in the physician's office. Arch Intern Med 2001; 161: 1599-1604.
51. Ashley JM, Jeor ST, Perumean-Chaney S, Schrage J, Bovee V,. Meal replacements in weight intervention. Obes Res 2001; 9 (Suppl 4): 312s-320s.
52. Ditschuneit HH, Flechtner-Mors M, Johnson TD, Adler G,. Metabolic and weight-loss effects of a long-term dietary intervention in obese patients. Am J Clin Nutr 1999; 69: 198-204.
53. Ditschuneit HH, Flechtner-Mors M,. Value of structured meals for weight management: risk factors and long-term weight maintenance. Obes Res 2001: 9 (Suppl 4): 284S-289S.
54. Leader NJ, Ryan L, Molyneaux L, Yue DK,. How best to use partial meal replacement in managing overweight or obese patients with poorly controlled type 2 diabetes. Obesity (Silver Spring, Md) 2013; 21: 251-253.
55. LeCheminant JD, Jacobsen DJ, Hall MA, Donnelly JE,. A comparison of meal replacements and medication in weight maintenance after weight loss. J Am Coll Nutr 2005; 24: 347-353.
56. Keogh JB, Clifton P,. The effect of meal replacements high in glycomacropeptide on weight loss and markers of cardiovascular disease risk. Am J Clin Nutr 2008; 87: 1602-1605.
57. Ashley JM, Herzog H, Clodfelter S, Bovee V, Schrage J, Pritsos C,. Nutrient adequacy during weight loss interventions: a randomized study in women comparing the dietary intake in a meal replacement group with a traditional food group. Nutr J 2007; 6: 12.
58. Fontaine KR, Yang D, Gadbury GL, et al. Results of soy-based meal replacement formula on weight, anthropometry, serum lipids & blood pressure during a 40-week clinical weight loss trial. Nutr J 2003; 2: 14.
59. Knowler WC, Barrett-Connor E, Fowler SE, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002; 346: 393-403.
60. U.S. Food and Drug Administration. Meridia (sibutramine): market withdrawal due to risk of serious cardiovascular events. 2010. Available at: http://www.fda.gov/safety/medwatch/safetyinformation/ safetyalertsforhumanmedicalproducts/ucm228830.htm. Accessed on September 9, 2013.
61. Allison DB, Gadde KM, Garvey WT, et al. Controlled-release phentermine/topiramate in severely obese adults: a randomized controlled trial (EQUIP). Obesity (Silver Spring, Md) 2012; 20: 330-342.
62. XE. XE Live Exchange Rates. 2014. Available at: www.xe.com. Accessed on February 24, 2014.
63. Archer E, Groessl EJ, Sui X, et al. An economic analysis of traditional and technology-based approaches to weight loss. Am J Prev Med 2012; 43: 176-182.
64. Cobiac LJ, Vos T, Barendregt JJ,. Cost-effectiveness of interventions to promote physical activity: a modelling study. PLoS Med 2009; 6: e1000110.
65. Foxcroft D,. Orlistat for the treatment of obesity: cost utility model. Obes Rev 2005; 6: 323-328.
66. Foxcroft D, Milne R,. Orlistat for the treatment of obesity: rapid review and cost-effectiveness model. Obes Rev 2000; 1: 121-126.
67. Hertzman P,. The cost effectiveness of orlistat in a 1-year weight-management programme for treating overweight and obese patients in Sweden: a treatment responder approach. Pharmacoeconomics 2005; 23: 1007-1020.
68. Iannazzo S, Zaniolo O, Pradelli L,. Economic evaluation of treatment with orlistat in Italian obese patients. Curr Med Res Opin 2007; 24: 63-74.
69. Lacey LA, Wolf A, O'Shea D, Erny S, Ruof J,. Cost-effectiveness of orlistat for the treatment of overweight and obese patients in Ireland. Int J Obes 2005; 29: 975-982.
70. Lamotte M, Annemans L, Lefever A, Nechelput M, Masure J,. A health economic model to assess the long-term effects and cost-effectiveness of orlistat in obese type 2 diabetic patients. Diabetes Care 2002; 25: 303-308.
71. Maahs D, de Serna DG, Kolotkin RL, et al. Randomized, double-blind, placebo-controlled trial of orlistat for weight loss in adolescents. Endocr Pract 2006; 12: 18-28.
72. Maetzel A, Ruof J, Covington M, Wolf A,. Economic evaluation of orlistat in overweight and obese patients with type 2 diabetes mellitus. Pharmacoeconomics 2003; 21: 501-512.
73. O'Meara S, Riemsma R, Shirran L, Mather L, Ter Riet G,. A rapid and systematic review of the clinical effectiveness and cost-effectiveness of orlistat in the management of obesity. Health Technol Assess 2001; 5: 1-81.
74. Roux L, Kuntz KM, Donaldson C, Goldie SJ,. Economic evaluation of weight loss interventions in overweight and obese women. Obesity 2006; 14: 1093-1106.
75. Ruof J, Golay A, Berne C, Collin C, Lentz J, Maetzel A,. Orlistat in responding obese type 2 diabetic patients: meta-analysis findings and cost-effectiveness as rationales for reimbursement in Sweden and Switzerland. Int J Obes 2005; 29: 517-523.
76. Van Baal PH, Van Den Berg M, Hoogenveen RT, Vijgen S, Engelfriet PM,. Cost-effectiveness of a low-calorie diet and orlistat for obese persons: modeling long-term health gains through prevention of obesity-related chronic diseases. Value Health 2008; 11: 1033-1040.
77. Light DW, Lexchin J,. Foreign free riders and the high price of US medicines. BMJ 2005; 331: 958-960.
78. Cobiac L, Vos T, Veerman L,. Cost effectiveness of Weight Watchers and the Lighten Up to a Healthy Lifestyle program. Aust N Z J Public Health 2010; 34: 240-247.
79. O'Meara S, Riemsma R, Shirran L, Mather L, ter Riet G,. A Systematic Review of the Clinical Effectiveness and Cost-Effectiveness of Sibutramine in the Management of Obesity. Health Technology Assessment; 2002;6.
80. Warren E, Brennan A, Akehurst R,. Cost-effectiveness of sibutramine in the treatment of obesity. Med Decis Making 2004; 24: 9-19.